Ardea Biosciences, Inc. Board of Directors under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Go...
April 23 2012 - 12:35PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Ardea Biosciences, Inc. (“Ardea” or the “Company”) (NASDAQ: RDEA)
related to the proposed acquisition of the Company by AstraZeneca.
The transaction is valued at approximately $1.26 billion or $32 per
share.
This investigation concerns whether the Board of Directors of
Ardea breached their fiduciary duties to stockholders by failing to
adequately shop the Company before agreeing to enter into the
proposed transaction, and whether the Company has disclosed all
material information to shareholders about the transaction. The
Company has seen substantial recent growth. Further, at least one
analyst has set a target price for the Company’s stock at $40.00
per share.
If you are a shareholder of Ardea, if you have information or
would like to learn more about our investigation, or if you wish to
discuss these matters or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Louis Boyarsky, Esquire, Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at
(888) 773-9224 or by email to shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Aug 2023 to Aug 2024